aldoxorubicin (INNO-206) / Xoma, LadRx, ImmunityBio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
aldoxorubicin (INNO-206) / LadRx
QUILT-88, NCT04390399: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Checkmark Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Hourglass Jul 2021 - Sep 2021 : Anticipated enrollment of Cohort C in metastatic 3L pancreatic cancer
Active, not recruiting
2
328
US
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
ImmunityBio, Inc.
Pancreatic Cancer
06/24
09/24
QUILT-3.071, NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Active, not recruiting
1b/2
332
US
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
ImmunityBio, Inc.
Colorectal Cancer Metastatic, mCRC
12/22
12/22
QUILT-3.067, NCT03387085: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Active, not recruiting
1/2
79
US
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
ImmunityBio, Inc.
Triple Negative Breast Cancer
09/23
10/23

Download Options